(1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide
3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide
3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine
Famotidina
Famotidinum
N-Sulfamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide

External IDs

L 643341 / MK-208 / YM-11170

Product Images

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Bci Famotidine	Tablet	40 mg	Oral	Baker Cummins Inc	Not applicable	Not applicable
Bci Famotidine	Tablet	20 mg	Oral	Baker Cummins Inc	Not applicable	Not applicable
Famotidine	Powder, for suspension	40 mg/5mL	Oral	Paddock Laboratories, Inc.	2010-05-28	2017-10-26
Famotidine 10mg	Tablet	10 mg	Oral	Laboratoire Riva Inc	Not applicable	Not applicable
Famotidine Injection	Solution	10 mg	Intravenous	Mylan Pharmaceuticals	Not applicable	Not applicable
Famotidine Injection	Solution	10 mg	Intravenous	Fresenius Kabi	Not applicable	Not applicable
Famotidine Injection	Solution	10 mg	Intravenous	Mylan Pharmaceuticals	Not applicable	Not applicable
Famotidine Injection	Solution	10 mg	Intravenous	Hospira, Inc.	Not applicable	Not applicable
Famotidine IV Injection	Solution	10 mg	Intravenous	Teva	Not applicable	Not applicable
Famotidine IV Injection	Solution	10 mg	Intravenous	Teva	Not applicable	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-famotidine Injectable	Solution	10 mg	Intravenous	Apotex Corporation	2003-11-17	2013-08-02
Apo-famotidine Injectable	Solution	10 mg	Intravenous	Apotex Corporation	2004-05-27	2013-08-02
Apo-famotidine Tab 20mg USP	Tablet	20 mg	Oral	Apotex Corporation	1993-12-31	Not applicable
Apo-famotidine Tab 40mg USP	Tablet	40 mg	Oral	Apotex Corporation	1993-12-31	Not applicable
Famotidine	Tablet	40 mg/1	Oral	bryant ranch prepack	2016-01-29	2018-05-31
Famotidine	Tablet	20 mg/1	Oral	Clinical Solutions Wholsesale	2001-04-16	2017-11-02
Famotidine	Tablet	40 mg/1	Oral	Directrx	2017-10-30	Not applicable
Famotidine	Tablet, film coated	20 mg/1	Oral	Mc Kesson	2001-04-16	Not applicable
Famotidine	Tablet, film coated	20 mg/1	Oral	Remedy Repack	2017-04-25	Not applicable
Famotidine	Tablet	20 mg/1	Oral	Mc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation	2009-07-01	2017-01-05

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
7 Select Acid Controller	Tablet	20 mg/1	Oral	7 Eleven	2014-08-05	Not applicable
Acid Control	Tablet	20 mg	Oral	Apotex Corporation	2014-04-28	Not applicable
Acid Control	Tablet	10 mg	Oral	Vita Health Products Inc	1998-10-27	Not applicable
Acid Control	Tablet	10 mg	Oral	Pendopharm Division Of De Pharmascience Inc	1997-09-08	2015-01-19
Acid Control	Tablet	10 mg	Oral	Teva	1997-06-17	Not applicable
Acid Control	Tablet	10 mg	Oral	Apotex Corporation	2000-07-11	Not applicable
Acid Control Original Strength	Tablet	10 mg/1	Oral	Medicine Shoppe International	2009-10-19	2017-11-30
Acid Controller	Tablet	20 mg/1	Oral	Shopko Stores Operating	2013-07-17	Not applicable
Acid Controller	Tablet	20 mg/1	Oral	Walgreen	2006-09-26	Not applicable
Acid Controller	Tablet	20 mg/1	Oral	H.E.B.	2016-09-14	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Acid Controller Complete	Famotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)	Tablet, chewable	Oral	Shopko Stores Operating	2013-06-05	2017-11-29
Acid Controller Complete	Famotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)	Tablet, chewable	Oral	Shopko Stores Operating	2013-06-05	2017-11-29
Acid Controller Complete	Famotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)	Tablet, chewable	Oral	Safeway	2008-08-06	2017-12-22
Acid Controller Complete dual action	Famotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)	Tablet, chewable	Oral	Walgreen	2008-07-30	Not applicable
Acid Controller Complete dual action	Famotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)	Tablet, chewable	Oral	Walgreen	2008-07-30	2018-03-29
Acid Reducer Complete	Famotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)	Tablet, chewable	Oral	Shopko Stores Operating	2016-01-06	Not applicable
Acid Reducer Complete	Famotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)	Tablet, chewable	Oral	Walgreen	2016-01-29	Not applicable
Acid Reducer Complete	Famotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)	Tablet, chewable	Oral	Rite Aid	2009-05-15	2018-04-01
Acid Reducer Complete	Famotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)	Tablet, chewable	Oral	Shopko Stores Operating	2016-01-12	Not applicable
Acid Reducer Complete	Famotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)	Tablet, chewable	Oral	Walgreen	2016-01-29	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Famotidine	Famotidine (2 mg/mL)	Injection, solution	Intravenous	Cantrell Drug Company	2014-06-11	Not applicable

International/Other Brands

Amfamox / Antodine / Confobos / Cronol / Digervin / Dispromil / Duovel / Durater / Famocid / Famosan / Famotep / Famox / Famoxal / Famtac / Famulcer / Fanosin / Fluxid / Gaster / Lecedil / Motiax / Mylanta AR / Notidin / Nulceran / Panalba / Pepcid / Pepcid RPD / Pepcidin / Pepcidine / Pepdine / Pepfamin / Quamatel / Renapepsa / Rubacina / Sedanium-R / Supertidine / Tairal / Tipodex / Ulfagel / Ulfamid / Ulgarine / Vagostal

Categories

UNII

5QZO15J2Z8

CAS number

76824-35-6

Weight

Average: 337.445
Monoisotopic: 337.044934829

Chemical Formula

C₈H₁₅N₇O₂S₃

InChI Key

XUFQPHANEAPEMJ-UHFFFAOYSA-N

InChI

InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)

IUPAC Name

3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N'-sulfamoylpropanimidamide

SMILES

NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1

Pharmacology

Indication

For the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD).

Associated Conditions

Pharmacodynamics

Famotidine, a competitive histamine H₂-receptor antagonist, is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Famotidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Famotidine include an increase in gastric bacterial flora such as nitrate-reducing organisms.

Mechanism of action

Famotidine binds competitively to H₂-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin.

Target	Actions	Organism
AHistamine H2 receptor	antagonist	Human

Absorption

The bioavailability of oral doses is 40-45%.

Volume of distribution

Not Available

Protein binding

15-20%

Metabolism

Hepatic.

Route of elimination

Renal clearance is 250-450 mL/min, indicating some tubular excretion.

Half life

2.5-3.5 hours

Clearance

renal cl=250-450 mL/min

Toxicity

Intravenous, mouse: LD₅₀ = 244.4mg/kg; Oral, mouse: LD₅₀ = 4686 mg/kg. Symptoms of overdose include emesis, restlessness, pallor of mucous membranes or redness of mouth and ears, hypotension, tachycardia and collapse.

Affected organisms

Humans and other mammals

Pathways

Pathway	Category
Famotidine Action Pathway	Drug action

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
2,5-Dimethoxy-4-ethylamphetamine	2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Famotidine.	Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine	2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative and stimulatory activities of Famotidine.	Experimental
3,4-Methylenedioxyamphetamine	3,4-Methylenedioxyamphetamine may decrease the sedative and stimulatory activities of Famotidine.	Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine	4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Famotidine.	Experimental, Illicit
Abexinostat	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Abexinostat.	Investigational
Aceprometazine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Aceprometazine.	Approved
Acrivastine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Acrivastine.	Approved
Agmatine	The serum concentration of Agmatine can be increased when it is combined with Famotidine.	Experimental, Investigational
Alcaftadine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Alcaftadine.	Approved
Alfuzosin	The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Famotidine.	Approved, Investigational
Alimemazine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Alimemazine.	Approved, Vet Approved
Amantadine	The risk or severity of QTc prolongation can be increased when Amantadine is combined with Famotidine.	Approved
Amifampridine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Amifampridine.	Approved
Amiodarone	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Amiodarone.	Approved, Investigational
Amitriptyline	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Amitriptyline.	Approved
Amodiaquine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Amodiaquine.	Approved, Investigational
Amoxapine	The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Famotidine.	Approved
Amphetamine	Amphetamine may decrease the sedative and stimulatory activities of Famotidine.	Approved, Illicit, Investigational
Anagrelide	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Anagrelide.	Approved
Antazoline	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Antazoline.	Approved
Apomorphine	The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Famotidine.	Approved, Investigational
Arformoterol	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Arformoterol.	Approved, Investigational
Aripiprazole	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Aripiprazole.	Approved, Investigational
Aripiprazole lauroxil	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Aripiprazole lauroxil.	Approved, Investigational
Arsenic trioxide	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Arsenic trioxide.	Approved, Investigational
Artemether	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Artemether.	Approved
Asenapine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Asenapine.	Approved
Astemizole	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Astemizole.	Approved, Withdrawn
Atazanavir	Famotidine can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Atomoxetine	The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Famotidine.	Approved
Azatadine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Azatadine.	Approved
Azelastine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Azelastine.	Approved
Azithromycin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Azithromycin.	Approved
Bedaquiline	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Bedaquiline.	Approved
Benzatropine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Benzatropine.	Approved
Benzphetamine	Benzphetamine may decrease the sedative and stimulatory activities of Famotidine.	Approved, Illicit
Benzylpenicilloyl Polylysine	Famotidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.	Approved
Bepridil	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Bepridil.	Approved, Withdrawn
Besifloxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Besifloxacin.	Approved
Betahistine	The therapeutic efficacy of Betahistine can be decreased when used in combination with Famotidine.	Approved, Investigational
Bilastine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Bilastine.	Approved, Investigational
Bortezomib	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Famotidine.	Approved, Investigational
Bosutinib	Famotidine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Brompheniramine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Brompheniramine.	Approved
Buclizine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Buclizine.	Approved
Buserelin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Buserelin.	Approved, Investigational
Butriptyline	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Butriptyline.	Approved
Carbinoxamine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Carbinoxamine.	Approved
Cefditoren	Famotidine can cause a decrease in the absorption of Cefditoren resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Cefpodoxime	Famotidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Vet Approved
Cefuroxime	Famotidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ceritinib	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ceritinib.	Approved
Cetirizine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Cetirizine.	Approved
Chlorcyclizine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Chlorcyclizine.	Approved
Chloroquine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Chloroquine.	Approved, Investigational, Vet Approved
Chlorphenamine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Chlorphenamine.	Approved
Chlorphentermine	Chlorphentermine may decrease the sedative and stimulatory activities of Famotidine.	Illicit, Withdrawn
Chlorpromazine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Chlorpromazine.	Approved, Investigational, Vet Approved
Chlorprothixene	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Chlorprothixene.	Approved, Investigational, Withdrawn
Choline	The serum concentration of Choline can be increased when it is combined with Famotidine.	Approved, Nutraceutical
Choline salicylate	The serum concentration of Choline salicylate can be increased when it is combined with Famotidine.	Approved, Nutraceutical
Cilostazol	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Cilostazol.	Approved, Investigational
Cimetidine	The serum concentration of Cimetidine can be increased when it is combined with Famotidine.	Approved, Investigational
Cinnarizine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Cinnarizine.	Approved, Investigational
Cinoxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Cinoxacin.	Approved, Investigational, Withdrawn
Ciprofloxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ciprofloxacin.	Approved, Investigational
Cisapride	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Cisapride.	Approved, Investigational, Withdrawn
Cisplatin	The serum concentration of Cisplatin can be increased when it is combined with Famotidine.	Approved
Citalopram	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Citalopram.	Approved
Clarithromycin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Clarithromycin.	Approved
Clemastine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Clemastine.	Approved, Investigational
Clomipramine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Clomipramine.	Approved, Investigational, Vet Approved
Clozapine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Clozapine.	Approved
Cocaine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Cocaine.	Approved, Illicit
Crizotinib	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Crizotinib.	Approved
CUDC-101	The risk or severity of QTc prolongation can be increased when Famotidine is combined with CUDC-101.	Investigational
CUDC-907	The risk or severity of QTc prolongation can be increased when Famotidine is combined with CUDC-907.	Investigational
Cyclizine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Cyclizine.	Approved
Cyproheptadine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Cyproheptadine.	Approved
Cysteamine	Famotidine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects.	Approved, Investigational
Dabrafenib	Famotidine can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Dasatinib	Famotidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Degarelix	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Degarelix.	Approved
Delamanid	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Delamanid.	Approved, Investigational
Delavirdine	Famotidine can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Desflurane	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Desflurane.	Approved
Desipramine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Desipramine.	Approved, Investigational
Desloratadine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Desloratadine.	Approved, Investigational
Deutetrabenazine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Deutetrabenazine.	Approved, Investigational
Dexbrompheniramine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Dexbrompheniramine.	Approved
Dexchlorpheniramine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Dexchlorpheniramine.	Experimental, Investigational
Dexchlorpheniramine maleate	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Dexchlorpheniramine maleate.	Approved
Dexmethylphenidate	The therapeutic efficacy of Dexmethylphenidate can be decreased when used in combination with Famotidine.	Approved, Investigational
Dextroamphetamine	Dextroamphetamine may decrease the sedative and stimulatory activities of Famotidine.	Approved, Illicit
Diethylpropion	Diethylpropion may decrease the sedative and stimulatory activities of Famotidine.	Approved, Illicit
Difloxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Difloxacin.	Vet Approved
Dimenhydrinate	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Dimenhydrinate.	Approved
Diphenhydramine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Diphenhydramine.	Approved, Investigational
Disopyramide	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Disopyramide.	Approved
Dofetilide	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Dofetilide.	Approved, Investigational
Dolasetron	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Dolasetron.	Approved, Investigational
Domperidone	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Domperidone.	Approved, Investigational, Vet Approved
Donepezil	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Donepezil.	Approved
Dopamine	The serum concentration of Dopamine can be increased when it is combined with Famotidine.	Approved
Dosulepin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Dosulepin.	Approved
Doxepin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Doxepin.	Approved, Investigational
Doxylamine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Doxylamine.	Approved, Vet Approved
Dronedarone	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Dronedarone.	Approved
Droperidol	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Droperidol.	Approved, Vet Approved
Ebastine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ebastine.	Approved, Investigational
Eliglustat	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Eliglustat.	Approved
Emedastine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Emedastine.	Approved
Enoxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Enoxacin.	Approved, Investigational
Entinostat	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Entinostat.	Investigational
Epinastine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Epinastine.	Approved, Investigational
Epinephrine	The serum concentration of Epinephrine can be increased when it is combined with Famotidine.	Approved, Vet Approved
Eribulin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Eribulin.	Approved, Investigational
Erlotinib	Famotidine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Erythromycin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Erythromycin.	Approved, Investigational, Vet Approved
Escitalopram	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Escitalopram.	Approved, Investigational
Estradiol	The excretion of Estradiol can be decreased when combined with Famotidine.	Approved, Investigational, Vet Approved
Ezogabine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ezogabine.	Approved, Investigational
Felbamate	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Felbamate.	Approved
Ferric ammonium citrate	Famotidine can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ferric Carboxymaltose	Famotidine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ferric cation	Famotidine can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ferric hydroxide	Famotidine can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.	Experimental
Ferric oxide	Famotidine can cause a decrease in the absorption of Ferric oxide resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ferric pyrophosphate	Famotidine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Experimental
Ferric subsulfate	Famotidine can cause a decrease in the absorption of Ferric subsulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Experimental
Ferric sulfate	Famotidine can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ferrous bisglycinate	Famotidine can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ferrous chloride	Famotidine can cause a decrease in the absorption of Ferrous chloride resulting in a reduced serum concentration and potentially a decrease in efficacy.	Experimental
Ferrous fumarate	Famotidine can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ferrous gluconate	Famotidine can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ferrous succinate	Famotidine can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ferrous sulfate	Famotidine can cause a decrease in the absorption of Ferrous sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Experimental
Ferumoxides	Famotidine can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ferumoxsil	Famotidine can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ferumoxytol	Famotidine can cause a decrease in the absorption of Ferumoxytol resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Fexofenadine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Fexofenadine.	Approved, Investigational
Fingolimod	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Fingolimod.	Approved, Investigational
Flecainide	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Flecainide.	Approved, Withdrawn
Fleroxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Fleroxacin.	Approved
Fluconazole	The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Famotidine.	Approved, Investigational
Flumequine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Flumequine.	Withdrawn
Fluoxetine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Flupentixol.	Approved, Investigational, Withdrawn
Formoterol	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Formoterol.	Approved, Investigational
Fosamprenavir	Famotidine can cause a decrease in the absorption of Fosamprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Foscarnet	The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Famotidine.	Approved
Furosemide	The excretion of Famotidine can be decreased when combined with Furosemide.	Approved, Vet Approved
Gadobenic acid	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Gadobenic acid.	Approved, Investigational
Galantamine	The risk or severity of QTc prolongation can be increased when Galantamine is combined with Famotidine.	Approved
Garenoxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Garenoxacin.	Investigational
Gatifloxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Gatifloxacin.	Approved, Investigational
Gefitinib	Famotidine can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Gemifloxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Gemifloxacin.	Approved, Investigational
Gepefrine	Gepefrine may decrease the sedative and stimulatory activities of Famotidine.	Experimental
Givinostat	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Givinostat.	Investigational
Gleptoferron	Famotidine can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.	Vet Approved
Goserelin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Goserelin.	Approved
Granisetron	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Granisetron.	Approved, Investigational
Grepafloxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Grepafloxacin.	Approved, Investigational, Withdrawn
Halofantrine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Halofantrine.	Approved
Haloperidol	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Haloperidol.	Approved
Histamine	The serum concentration of Histamine can be increased when it is combined with Famotidine.	Approved, Investigational
Histrelin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Histrelin.	Approved
Hyaluronidase	The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Famotidine.	Approved, Investigational
Hydroxyamphetamine	Hydroxyamphetamine may decrease the sedative and stimulatory activities of Famotidine.	Approved
Hydroxychloroquine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Hydroxychloroquine.	Approved
Hydroxyzine	The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Famotidine.	Approved
Ibandronate	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Famotidine.	Approved, Investigational
Ibutilide	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ibutilide.	Approved
Iloperidone	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Iloperidone.	Approved
Imatinib	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Imatinib.	Approved
Imipramine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Imipramine.	Approved
Indacaterol	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Indacaterol.	Approved
Indapamide	The risk or severity of QTc prolongation can be increased when Indapamide is combined with Famotidine.	Approved
Indinavir	Famotidine can cause a decrease in the absorption of Indinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Iofetamine I-123	Iofetamine I-123 may decrease the sedative and stimulatory activities of Famotidine.	Approved
Iron	Famotidine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Iron Dextran	Famotidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Vet Approved
Iron isomaltoside 1000	Famotidine can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Iron saccharate	Famotidine can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Isoflurane	The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Famotidine.	Approved, Vet Approved
Isradipine	The risk or severity of QTc prolongation can be increased when Isradipine is combined with Famotidine.	Approved, Investigational
Itraconazole	Famotidine can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Ivabradine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ivabradine.	Approved
Ivosidenib	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ivosidenib.	Approved, Investigational
Ketoconazole	Famotidine can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Ketotifen	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ketotifen.	Approved
Lamivudine	The serum concentration of Lamivudine can be increased when it is combined with Famotidine.	Approved, Investigational
Lapatinib	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Lapatinib.	Approved, Investigational
Ledipasvir	Famotidine can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Lenvatinib	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Lenvatinib.	Approved, Investigational
Leuprolide	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Leuprolide.	Approved, Investigational
Levocabastine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Levocabastine.	Approved, Investigational
Levocetirizine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Levocetirizine.	Approved
Levofloxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Levofloxacin.	Approved, Investigational
Levomethadyl Acetate	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Levomethadyl Acetate.	Approved, Investigational
Lisdexamfetamine	Lisdexamfetamine may decrease the sedative and stimulatory activities of Famotidine.	Approved, Investigational
Lithium cation	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Lithium cation.	Experimental
Lomefloxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Lomefloxacin.	Approved, Investigational
Lopinavir	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Lopinavir.	Approved
Loratadine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Loratadine.	Approved, Investigational
Lumefantrine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Lumefantrine.	Approved
Macimorelin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Macimorelin.	Approved, Investigational
Maprotiline	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Maprotiline.	Approved, Investigational
Mefloquine	The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Famotidine.	Approved, Investigational
Memantine	The serum concentration of Memantine can be increased when it is combined with Famotidine.	Approved, Investigational
Mephedrone	Mephedrone may decrease the sedative and stimulatory activities of Famotidine.	Investigational
Mephentermine	Mephentermine may decrease the sedative and stimulatory activities of Famotidine.	Approved
Mepyramine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Mepyramine.	Approved, Vet Approved
Mequitazine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Mequitazine.	Approved
Mesalazine	The therapeutic efficacy of Mesalazine can be decreased when used in combination with Famotidine.	Approved
Mesoridazine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Mesoridazine.	Approved, Investigational
Metformin	The serum concentration of Metformin can be increased when it is combined with Famotidine.	Approved
Methadone	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Methadone.	Approved
Methamphetamine	Methamphetamine may decrease the sedative and stimulatory activities of Famotidine.	Approved, Illicit
Methotrimeprazine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Methotrimeprazine.	Approved, Investigational
Methoxyphenamine	Methoxyphenamine may decrease the sedative and stimulatory activities of Famotidine.	Experimental
Methylphenidate	The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Famotidine.	Approved, Investigational
Metoclopramide	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Metoclopramide.	Approved, Investigational
Metronidazole	The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Famotidine.	Approved
Midomafetamine	Midomafetamine may decrease the sedative and stimulatory activities of Famotidine.	Experimental, Illicit, Investigational
Mifepristone	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Mifepristone.	Approved, Investigational
Mirabegron	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Mirabegron.	Approved
Mirtazapine	The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Famotidine.	Approved
MMDA	MMDA may decrease the sedative and stimulatory activities of Famotidine.	Experimental, Illicit
Mocetinostat	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Mocetinostat.	Investigational
Moexipril	The risk or severity of QTc prolongation can be increased when Moexipril is combined with Famotidine.	Approved
Moxifloxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Moxifloxacin.	Approved, Investigational
Nafamostat	The serum concentration of Nafamostat can be increased when it is combined with Famotidine.	Approved, Investigational
Nalidixic Acid	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Nalidixic Acid.	Approved, Investigational
Nelfinavir	Famotidine can cause a decrease in the absorption of Nelfinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Nemonoxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Nemonoxacin.	Investigational
Nicardipine	The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Famotidine.	Approved, Investigational
Nilotinib	Famotidine can cause a decrease in the absorption of Nilotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Nitroprusside	Famotidine can cause a decrease in the absorption of Nitroprusside resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Norepinephrine	The serum concentration of Norepinephrine can be increased when it is combined with Famotidine.	Approved
Norfloxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Norfloxacin.	Approved
Nortriptyline	The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Famotidine.	Approved
Octreotide	The risk or severity of QTc prolongation can be increased when Octreotide is combined with Famotidine.	Approved, Investigational
Ofloxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ofloxacin.	Approved
Olanzapine	The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Famotidine.	Approved, Investigational
Olodaterol	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Olodaterol.	Approved
Olopatadine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Olopatadine.	Approved
Ondansetron	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ondansetron.	Approved
Orbifloxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Orbifloxacin.	Vet Approved
Orphenadrine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Orphenadrine.	Approved
Oxaliplatin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Oxaliplatin.	Approved, Investigational
Oxatomide	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Oxatomide.	Investigational
Oxolinic acid	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Oxolinic acid.	Experimental
Oxytocin	The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Famotidine.	Approved, Vet Approved
Paliperidone	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Paliperidone.	Approved
Panobinostat	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Panobinostat.	Approved, Investigational
Papaverine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Papaverine.	Approved, Investigational
Paroxetine	The risk or severity of QTc prolongation can be increased when Paroxetine is combined with Famotidine.	Approved, Investigational
Pasireotide	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Pasireotide.	Approved
Pazopanib	Famotidine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Pazufloxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Pazufloxacin.	Investigational
Pefloxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Pefloxacin.	Approved
Pentamidine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Pentamidine.	Approved, Investigational
Perflubutane	Famotidine can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Perflutren	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Perflutren.	Approved
Pheniramine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Pheniramine.	Approved
Phentermine	Phentermine may decrease the sedative and stimulatory activities of Famotidine.	Approved, Illicit
Pimozide	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Pimozide.	Approved
Pipemidic acid	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Pipemidic acid.	Experimental
Piromidic acid	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Piromidic acid.	Experimental
Pitolisant	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Pitolisant.	Approved, Investigational
Posaconazole	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Posaconazole.	Approved, Investigational, Vet Approved
Pracinostat	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Pracinostat.	Investigational
Pramipexole	The serum concentration of Pramipexole can be increased when it is combined with Famotidine.	Approved, Investigational
Prazosin	The serum concentration of Prazosin can be increased when it is combined with Famotidine.	Approved
Primaquine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Primaquine.	Approved
Probucol	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Probucol.	Approved, Investigational
Procainamide	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Procainamide.	Approved
Promazine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Promazine.	Approved, Vet Approved
Promethazine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Promethazine.	Approved, Investigational
Propafenone	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Propafenone.	Approved
Propofol	The risk or severity of QTc prolongation can be increased when Propofol is combined with Famotidine.	Approved, Investigational, Vet Approved
Protriptyline	The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Famotidine.	Approved
Prulifloxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Prulifloxacin.	Investigational
Prussian blue	Famotidine can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Pseudoephedrine	Pseudoephedrine may decrease the sedative and stimulatory activities of Famotidine.	Approved
Quetiapine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Quetiapine.	Approved
Quinidine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Quinidine.	Approved, Investigational
Quinine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Quinine.	Approved
Ranitidine	The serum concentration of Ranitidine can be increased when it is combined with Famotidine.	Approved
Ranolazine	The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Famotidine.	Approved, Investigational
Reserpine	The serum concentration of Reserpine can be increased when it is combined with Famotidine.	Approved, Investigational
Ribociclib	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ribociclib.	Approved, Investigational
Ricolinostat	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ricolinostat.	Investigational
Rilpivirine	Famotidine can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Risedronate	Famotidine can cause an increase in the absorption of Risedronate resulting in an increased serum concentration and potentially a worsening of adverse effects.	Approved, Investigational
Risperidone	The risk or severity of QTc prolongation can be increased when Risperidone is combined with Famotidine.	Approved, Investigational
Ritobegron	Ritobegron may decrease the sedative and stimulatory activities of Famotidine.	Investigational
Ritonavir	The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Famotidine.	Approved, Investigational
Romidepsin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Romidepsin.	Approved, Investigational
Rosoxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Rosoxacin.	Approved, Investigational
Roxithromycin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Roxithromycin.	Approved, Investigational, Withdrawn
Rufloxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Rufloxacin.	Experimental
Rupatadine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Rupatadine.	Approved
Salbutamol	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Salbutamol.	Approved, Vet Approved
Salmeterol	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Salmeterol.	Approved
Saquinavir	Famotidine can cause an increase in the absorption of Saquinavir resulting in an increased serum concentration and potentially a worsening of adverse effects.	Approved, Investigational
Sarafloxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Sarafloxacin.	Vet Approved, Withdrawn
Sertraline	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Sertraline.	Approved
Sevoflurane	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Sevoflurane.	Approved, Vet Approved
Sitafloxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Sitafloxacin.	Experimental, Investigational
Sodium feredetate	Famotidine can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Experimental
Solifenacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Solifenacin.	Approved
Sorafenib	The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Famotidine.	Approved, Investigational
Sotalol	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Sotalol.	Approved
Sparfloxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Sparfloxacin.	Approved, Investigational
Sulfamethoxazole	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Sulfamethoxazole.	Approved
Sulfisoxazole	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Sulfisoxazole.	Approved, Vet Approved
Sulpiride	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Sulpiride.	Approved, Investigational
Sultopride	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Sultopride.	Experimental
Sunitinib	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Sunitinib.	Approved, Investigational
Tamoxifen	The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Famotidine.	Approved
Tandutinib	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Tandutinib.	Investigational
Technetium Tc-99m ciprofloxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Technetium Tc-99m ciprofloxacin.	Investigational
Telavancin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Telavancin.	Approved
Telithromycin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Telithromycin.	Approved
Temafloxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Temafloxacin.	Withdrawn
Terbutaline	The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Famotidine.	Approved
Terfenadine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Terfenadine.	Approved, Withdrawn
Teriflunomide	The serum concentration of Famotidine can be increased when it is combined with Teriflunomide.	Approved
Terlipressin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Terlipressin.	Approved, Investigational
Terodiline	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Terodiline.	Experimental
Tetrabenazine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Tetrabenazine.	Approved, Investigational
Tetracycline	The excretion of Famotidine can be decreased when combined with Tetracycline.	Approved, Vet Approved
Tetraethylammonium	The serum concentration of Tetraethylammonium can be increased when it is combined with Famotidine.	Experimental, Investigational
Tetraferric tricitrate decahydrate	Famotidine can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Thioridazine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Thioridazine.	Approved, Withdrawn
Thiothixene	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Thiothixene.	Approved
Tizanidine	The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Famotidine.	Approved, Investigational
Tolterodine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Tolterodine.	Approved, Investigational
Toremifene	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Toremifene.	Approved, Investigational
Trazodone	The risk or severity of QTc prolongation can be increased when Trazodone is combined with Famotidine.	Approved, Investigational
Treprostinil	The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Famotidine.	Approved, Investigational
Trimethoprim	The risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Famotidine.	Approved, Vet Approved
Trimipramine	The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Famotidine.	Approved
Triprolidine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Triprolidine.	Approved
Triptorelin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Triptorelin.	Approved, Vet Approved
Trovafloxacin	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Trovafloxacin.	Approved, Investigational, Withdrawn
Tucidinostat	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Tucidinostat.	Investigational
Valproic Acid	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Valproic Acid.	Approved, Investigational
Vandetanib	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Vandetanib.	Approved
Vardenafil	The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Famotidine.	Approved
Varenicline	Famotidine may decrease the excretion rate of Varenicline which could result in a higher serum level.	Approved, Investigational
Vemurafenib	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Vemurafenib.	Approved
Venlafaxine	The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Famotidine.	Approved
Vilanterol	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Vilanterol.	Approved
Voriconazole	The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Famotidine.	Approved, Investigational
Vorinostat	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Vorinostat.	Approved, Investigational
Zidovudine	The excretion of Zidovudine can be decreased when combined with Famotidine.	Approved
Ziprasidone	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ziprasidone.	Approved
Zuclopenthixol	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Zuclopenthixol.	Approved, Investigational

Food Interactions

Avoid alcohol.
Limit caffeine intake.
Take without regard to meals, food may slightly increase the product's bioavailability.

References

Synthesis Reference

Montserrat Ballester-Rodes, Francisco E. Palomo-Nicolau, Antonio L. Palomo-Coli, "Famotidine polymorphic forms and their preparation process." U.S. Patent US5021582, issued March, 1987.

US5021582

General References

Not Available

External Links

Human Metabolome Database: HMDB0001919
KEGG Drug: D00318
PubChem Compound: 3325
PubChem Substance: 46507397
ChemSpider: 3208
BindingDB: 50036754
ChEBI: 4975
ChEMBL: CHEMBL902
Therapeutic Targets Database: DAP000341
PharmGKB: PA449586
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
PDRhealth: PDRhealth Drug Page
Wikipedia: Famotidine

ATC Codes

A02BA03 — Famotidine

A02BA53 — Famotidine, combinations

AHFS Codes

56:28.12 — Histamine H2-antagonists

FDA label

Download (1.05 MB)

MSDS

Download (73.8 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Not Available	Healthy Volunteers / Lupus / Psoriasis	1
1	Completed	Not Available	Human Immunodeficiency Virus (HIV) Infections	1
1	Completed	Basic Science	Drug-Drug Interaction (DDI)	1
1	Completed	Basic Science	Healthy Volunteers	1
1	Completed	Health Services Research	Healthy Volunteers	1
1	Completed	Screening	Fibrosis	1
1	Completed	Treatment	Bioavailability	2
1	Completed	Treatment	Cancers / Colorectal Cancers / Lung Cancer Non-Small Cell Cancer (NSCLC) / Melanoma / Thyroid Papillary Carcinoma	1
1	Completed	Treatment	Healthy Volunteers	2
1	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Infection, Human Immunodeficiency Virus I	1
1	Completed	Treatment	Psoriasis	1
1	Recruiting	Basic Science	Healthy Volunteers	1
1	Recruiting	Treatment	Diseases of Oesophagus Stomach and Duodenum	1
1, 2	Recruiting	Treatment	Colorectal Cancers	1
2	Active Not Recruiting	Treatment	Malignant Neoplasm of Stomach	1
2	Completed	Treatment	Cerebrovascular Accident, Acute / Edema of the cerebrum	1
2	Completed	Treatment	Dyskinesias	1
2	Not Yet Recruiting	Treatment	Plasmodium Infections	1
2	Not Yet Recruiting	Treatment	Pulmonary Arterial Hypertension (PAH) / Right Heart Failure	1
2	Recruiting	Treatment	HNSCC / HPV-Related Squamous Cell Carcinoma	1
2	Recruiting	Treatment	Plasma Cell Myeloma	1
2, 3	Completed	Treatment	Malaria caused by Plasmodium falciparum	1
2, 3	Completed	Treatment	Reflux, Gastroesophageal	1
2, 3	Recruiting	Treatment	Schizophrenic Disorders	1
3	Completed	Prevention	Ulcers	1
3	Completed	Treatment	Erosive Esophagitis(EE)	1
3	Completed	Treatment	Peptic Ulcer Bleeding / Upper Gastrointestinal Hemorrhage	1
3	Completed	Treatment	Reflux, Gastroesophageal	1
3	Not Yet Recruiting	Treatment	Fallopian Tube Cancer / Ovarian Epithelial Cancer / Primary Peritoneal Carcinoma	2
3	Not Yet Recruiting	Treatment	Malaria caused by Plasmodium falciparum	1
4	Active Not Recruiting	Prevention	Peptic Ulcers	1
4	Completed	Not Available	Human Immunodeficiency Virus (HIV)	1
4	Completed	Not Available	Human Immunodeficiency Virus (HIV) Infections	1
4	Completed	Prevention	Marginal Ulcers	1
4	Completed	Prevention	Peptic Ulcer/Erosions	1
4	Completed	Prevention	Ulcers	1
4	Completed	Treatment	Heartburn	1
4	Completed	Treatment	Juvenile Idiopathic Arthritis (JIA)	1
4	Completed	Treatment	Schizophrenic Disorders	1
4	Recruiting	Treatment	Rheumatoid Arthritis	1
4	Unknown Status	Treatment	Aspirin / Indigestion	1
Not Available	Active Not Recruiting	Treatment	Metastatic Melanoma	1
Not Available	Completed	Not Available	Anemias / Iron Deficiency / Plasmodium Infections / Schistosomiasis Infection	1
Not Available	Completed	Not Available	Community Acquired Pneumonia (CAP) / Gastro-esophageal Reflux Disease (GERD)	1
Not Available	Completed	Not Available	Healthy Volunteers	2
Not Available	Completed	Not Available	Rhytidoplasty	1
Not Available	Completed	Treatment	Plasmodium Infections	1
Not Available	Recruiting	Prevention	Peptic Ulcers	2
Not Available	Recruiting	Supportive Care	Cancer, Breast / Prophylaxis against postoperative nausea and vomiting	1
Not Available	Recruiting	Treatment	Malignant Neoplasm of Stomach	1
Not Available	Unknown Status	Not Available	Parasitemia	1

Pharmacoeconomics

Manufacturers

Lupin ltd
Navinta llc
Salix pharmaceuticals inc
Akorn strides llc
Apotex inc richmond hill
Apothecon inc div bristol myers squibb
App pharmaceuticals llc
Baxter healthcare corp anesthesia and critical care
Baxter healthcare corp
Bedford laboratories div ben venue laboratories inc
Hospira inc
Ben venue laboratories inc
Claris lifesciences ltd
Abbott laboratories
Baxter healthcare internati0nal specialty therapies div
Merck research laboratories div merck co inc
L perrigo co
Schwarz pharma inc
Actavis elizabeth llc
Alembic ltd
Apotex inc
Carlsbad technology inc
Dr reddys laboratories ltd
Genpharm inc
Ivax pharmaceuticals inc sub teva pharmaceuticals usa
Mutual pharmaceutical co inc
Mylan pharmaceuticals inc
Perrigo co
Ranbaxy laboratories inc
Sandoz inc
Teva pharmaceuticals usa inc
Watson laboratories inc
Wockhardt ltd
Wockhardt americas inc

Packagers

Advanced Pharmaceutical Services Inc.
Akorn Inc.
Amerisource Health Services Corp.
APP Pharmaceuticals
A-S Medication Solutions LLC
Atlantic Biologicals Corporation
Baxter International Inc.
Bedford Labs
Ben Venue Laboratories Inc.
Bryant Ranch Prepack
Cardinal Health
Carlsbad Technology Inc.
Chain Drug
Corepharma LLC
CVS Pharmacy
Dispensing Solutions
Diversified Healthcare Services Inc.
Doctor Reddys Laboratories Ltd.
H.J. Harkins Co. Inc.
Heartland Repack Services LLC
Hospira Inc.
Ivax Pharmaceuticals
Johnson & Johnson Healthcare
Kaiser Foundation Hospital
Lake Erie Medical and Surgical Supply
Legacy Pharmaceuticals Packaging LLC
Lupin Pharmaceuticals Inc.
Major Pharmaceuticals
Mckesson Corp.
Medisca Inc.
Merck & Co.
Murfreesboro Pharmaceutical Nursing Supply
Mylan
Northstar Rx LLC
Nucare Pharmaceuticals Inc.
PCA LLC
PD-Rx Pharmaceuticals Inc.
Perrigo Co.
Pharmaceutical Utilization Management Program VA Inc.
Pharmedium
Physicians Total Care Inc.
Preferred Pharmaceuticals Inc.
Prepackage Specialists
Prepak Systems Inc.
Rebel Distributors Corp.
Redpharm Drug
Remedy Repack
Salix Pharmaceuticals
Sandhills Packaging Inc.
Southwood Pharmaceuticals
Strides Arcolab Limited
Teva Pharmaceutical Industries Ltd.
UDL Laboratories
Vangard Labs Inc.
Walgreen Co.
Watson Pharmaceuticals
Wockhardt Ltd.
Yung Shin Pharmaceutical Industry Ltd.
Zydus Pharmaceuticals

Dosage forms

Form	Route	Strength
Tablet, chewable	Oral
Tablet, coated	Oral
For suspension	Oral	40 mg/5mL
Injection	Intravenous	10 mg/mL
Injection, solution	Intravenous	10 mg/mL
Injection, solution	Intravenous	2 mg/mL
Injection, solution	Intravenous	20 mg/50mL
Powder, for solution	Oral	40 mg/5mL
Powder, for suspension	Oral	40 mg/5mL
Tablet	Oral	10 mg/1
Tablet	Oral	40 mg/1
Tablet, film coated	Oral	40 mg/1
Tablet, film coated, extended release	Oral	10 mg/1
Solution	Intravenous	10 mg
Tablet	Oral	20 mg/1
Tablet	Oral	10 mg
Tablet, chewable	Oral	20 mg/1
Tablet, film coated	Oral	20 mg/1
Tablet, film coated	Oral	10 mg/1
Tablet	Oral	20 mg
Tablet	Oral	40 mg
Tablet, coated	Oral	10 mg/1

Prices

Unit description	Cost	Unit
Pepcid 30 40 mg tablet Bottle	125.5USD	bottle
Pepcid 40 mg/5ml Suspension 50ml Bottle	123.88USD	bottle
Pepcid 30 20 mg tablet Bottle	64.13USD	bottle
Mylanta Double-Strength 400-400-40 mg/5ml Suspension 710ml Bottle	10.15USD	bottle
Mylanta 200-200-20 mg/5ml Suspension 710ml Bottle	9.23USD	bottle
Mylanta 200-200-20 mg/5ml Suspension 355ml Bottle	7.99USD	bottle
Mylanta Double-Strength 400-400-40 mg/5ml Suspension 355ml Bottle	7.99USD	bottle
Famotidine 40 mg tablet	3.43USD	tablet
Pepcid 40 mg tablet	3.02USD	tablet
Famotidine powder	2.74USD	g
Famotidine 20 mg tablet	1.76USD	tablet
Pepcid 20 mg tablet	1.6USD	tablet
Apo-Famotidine 40 mg Tablet	1.11USD	tablet
Mylan-Famotidine 40 mg Tablet	1.11USD	tablet
Novo-Famotidine 40 mg Tablet	1.11USD	tablet
Nu-Famotidine 40 mg Tablet	1.11USD	tablet
Pepcid ac 10 mg tablet	0.72USD	tablet
Famotidine 40 mg/4 ml vial	0.71USD	ml
Famotidine 500 mg/50 ml vial	0.71USD	ml
Apo-Famotidine 20 mg Tablet	0.62USD	tablet
Mylan-Famotidine 20 mg Tablet	0.62USD	tablet
Novo-Famotidine 20 mg Tablet	0.62USD	tablet
Nu-Famotidine 20 mg Tablet	0.62USD	tablet
Pepcid ac 20 mg tablet	0.58USD	tablet
Famotidine-ns 20 mg/10 ml syrg	0.54USD	ml
Pepcid ac 10 mg gelcap	0.48USD	capsule
Pepcid complete tablet chew	0.4USD	tablet
Famotidine 20 mg/2 ml vial	0.36USD	ml
Famotidine 10 mg/ml vial	0.28USD	ml
CVS Pharmacy acid controller 20 mg tablet	0.24USD	tablet
CVS Pharmacy acid controller tablet	0.24USD	tablet
Acid reducer 20 mg tablet	0.22USD	tablet
Acid controller 10 mg tablet	0.21USD	tablet
Mylanta gas 125 mg tablet chew	0.16USD	tablet
Acid reducer 10 mg tablet	0.15USD	tablet
Famotidine 10 mg tablet	0.15USD	tablet
Famotidine 20 mg piggyback	0.13USD	ml
Mylanta gelcap	0.12USD	capsule
Mylanta ultimate-strength tablet	0.07USD	tablet
Mylanta ultra chew tablet	0.06USD	tablet
Pv acid reducer 10 mg tablet	0.05USD	tablet
Mylanta liq	0.02USD	ml
Mylanta supreme antacid liq	0.02USD	ml

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US5075114	No	1993-05-23	2010-05-23
CA2178277	No	2000-11-14	2016-06-05
CA2052679	No	1997-12-02	2011-08-21
US6221392	No	1998-04-09	2018-04-09
US6024981	No	1998-04-09	2018-04-09
US5854267	Yes	1996-06-29	2016-06-29
US6814978	Yes	2002-02-26	2022-02-26
US5989588	Yes	1998-03-30	2018-03-30
US8067451	No	2006-07-18	2026-07-18
US8501228	No	2006-07-18	2026-07-18
US8318202	No	2006-07-18	2026-07-18
US8449910	No	2006-07-18	2026-07-18
US8309127	No	2006-07-18	2026-07-18
US8067033	No	2006-07-18	2026-07-18
US5667794	Yes	1995-11-02	2015-11-02

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	163.5 °C	PhysProp
water solubility	1000 mg/L (at 20 °C)	MERCK INDEX (1996)
logP	-0.64	ISLAM,MS & NARURKAR,MM (1993)

Predicted Properties

Property	Value	Source
Water Solubility	0.271 mg/mL	ALOGPS
logP	-0.2	ALOGPS
logP	-2	ChemAxon
logS	-3.1	ALOGPS
pKa (Strongest Acidic)	9.29	ChemAxon
pKa (Strongest Basic)	8.38	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	8	ChemAxon
Hydrogen Donor Count	4	ChemAxon
Polar Surface Area	175.83 Å²	ChemAxon
Rotatable Bond Count	6	ChemAxon
Refractivity	80.46 m³·mol^-1	ChemAxon
Polarizability	32.02 Å³	ChemAxon
Number of Rings	1	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9156
Blood Brain Barrier	+	0.9382
Caco-2 permeable	-	0.8957
P-glycoprotein substrate	Non-substrate	0.5839
P-glycoprotein inhibitor I	Non-inhibitor	0.9044
P-glycoprotein inhibitor II	Non-inhibitor	0.8701
Renal organic cation transporter	Non-inhibitor	0.6802
CYP450 2C9 substrate	Non-substrate	0.7898
CYP450 2D6 substrate	Non-substrate	0.9115
CYP450 3A4 substrate	Non-substrate	0.7558
CYP450 1A2 substrate	Non-inhibitor	0.9045
CYP450 2C9 inhibitor	Non-inhibitor	0.9071
CYP450 2D6 inhibitor	Non-inhibitor	0.9231
CYP450 2C19 inhibitor	Non-inhibitor	0.9025
CYP450 3A4 inhibitor	Non-inhibitor	0.8309
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9297
Ames test	Non AMES toxic	0.5827
Carcinogenicity	Non-carcinogens	0.9182
Biodegradation	Not ready biodegradable	0.9324
Rat acute toxicity	1.9523 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.8366
hERG inhibition (predictor II)	Inhibitor	0.6481

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
MS/MS Spectrum - Quattro_QQQ 10V, N/A	LC-MS/MS	splash10-000i-0029000000-087ab7a1109f0568738d
MS/MS Spectrum - Quattro_QQQ 25V, N/A	LC-MS/MS	splash10-0udi-0900000000-d8a9ef8fc58c0c705232
MS/MS Spectrum - Quattro_QQQ 40V, N/A	LC-MS/MS	splash10-000i-0900000000-e245f325e8c6f31a5fd0
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
MS/MS Spectrum - Linear Ion Trap , negative	LC-MS/MS	splash10-0005-0940000000-a2bd7381011d29592cea
MS/MS Spectrum - Linear Ion Trap , positive	LC-MS/MS	splash10-0a4i-0090000000-10306158f008021f19a5
MS/MS Spectrum - Linear Ion Trap , positive	LC-MS/MS	splash10-014i-0090000000-90a70a7303c968311864
MS/MS Spectrum - Linear Ion Trap , positive	LC-MS/MS	splash10-001i-0090000000-ac0250ad61059e58f431
MS/MS Spectrum - Linear Ion Trap , positive	LC-MS/MS	splash10-0002-0090000000-235724a37e50732fdf94
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0a4r-0950000000-0c16a77af1ba782fa15a
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0a4r-0950000000-02af106b93d1423b1342
1H NMR Spectrum	1D NMR	Not Applicable
[1H,13C] 2D NMR Spectrum	2D NMR	Not Applicable

Taxonomy

Description: This compound belongs to the class of organic compounds known as 2,4-disubstituted thiazoles. These are compounds containing a thiazole ring substituted at the positions 2 and 3.
Kingdom: Organic compounds
Super Class: Organoheterocyclic compounds
Class: Azoles
Sub Class: Thiazoles
Direct Parent: 2,4-disubstituted thiazoles
Alternative Parents: Organic sulfuric acids and derivatives / Heteroaromatic compounds / Guanidines / Sulfenyl compounds / Propargyl-type 1,3-dipolar organic compounds / Dialkylthioethers / Azacyclic compounds / Amidines / Organopnictogen compounds / Organic oxidesHydrocarbon derivatives
show 1 more
Substituents: 2,4-disubstituted 1,3-thiazole / Organic sulfuric acid or derivatives / Heteroaromatic compound / Guanidine / Amidine / Azacycle / Dialkylthioether / Organic 1,3-dipolar compound / Propargyl-type 1,3-dipolar organic compound / Sulfenyl compound
show 9 more
Molecular Framework: Aromatic heteromonocyclic compounds
External Descriptors: sulfonamide, guanidines, 1,3-thiazole (CHEBI:4975)

Targets

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	300	N/A	N/A	7904648

Details1. Histamine H2 receptor

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Antagonist

General Function: Histamine receptor activity
Specific Function: The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and diff...
Gene Name: HRH2
Uniprot ID: P25021
Uniprot Name: Histamine H2 receptor
Molecular Weight: 40097.65 Da

References

Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Fukuda M, Tanaka S, Suzuki S, Kusama K, Kaneko T, Sakashita H: Cimetidine induces apoptosis of human salivary gland tumor cells. Oncol Rep. 2007 Mar;17(3):673-8. [PubMed:17273750]
Takahashi HK, Watanabe T, Yokoyama A, Iwagaki H, Yoshino T, Tanaka N, Nishibori M: Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes. Mol Pharmacol. 2006 Aug;70(2):450-3. Epub 2006 May 24. [PubMed:16723495]
Kesiova M, Alexandrova A, Yordanova N, Kirkova M, Todorov S: Effects of diphenhydramine and famotidine on lipid peroxidation and activities of antioxidant enzymes in different rat tissues. Pharmacol Rep. 2006 Mar-Apr;58(2):221-8. [PubMed:16702624]
Lesclous P, Schramm F, Gallina S, Baroukh B, Guez D, Saffar JL: Histamine mediates osteoclastic resorption only during the acute phase of bone loss in ovariectomized rats. Exp Physiol. 2006 May;91(3):561-70. Epub 2006 Mar 2. [PubMed:16513821]
Amagase K, Okabe S: On the mechanisms underlying histamine induction of gastric mucosal lesions in rats with partial gastric vascular occlusion. J Pharmacol Sci. 2003 Jun;92(2):124-36. [PubMed:12832840]
Weydert JA, Ball TM, Davis MF: Systematic review of treatments for recurrent abdominal pain. Pediatrics. 2003 Jan;111(1):e1-11. [PubMed:12509588]
Miyata K, Kamato T, Nishida A, Honda K: Studies on the mechanism for the gastric mucosal protection by famotidine in rats. Jpn J Pharmacol. 1991 Feb;55(2):211-22. [PubMed:2067140]
Leurs R, Brozius MM, Smit MJ, Bast A, Timmerman H: Effects of histamine H1-, H2- and H3-receptor selective drugs on the mechanical activity of guinea-pig small and large intestine. Br J Pharmacol. 1991 Jan;102(1):179-85. [PubMed:1646056]
Inan A, Sen M, Surgit O, Ergin M, Bozer M: Effects of the histamine H2 receptor antagonist famotidine on the healing of colonic anastomosis in rats. Clinics (Sao Paulo). 2009;64(6):567-70. [PubMed:19578661]
Ojiako K, Shingala H, Schorr C, Gerber DR: Famotidine versus pantoprazole for preventing bleeding in the upper gastrointestinal tract of critically ill patients receiving mechanical ventilation. Am J Crit Care. 2008 Mar;17(2):142-7. [PubMed:18310651]

Enzymes

Details1. Cytochrome P450 2C19

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Steroid hydroxylase activity
Specific Function: Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name: CYP2C19
Uniprot ID: P33261
Uniprot Name: Cytochrome P450 2C19
Molecular Weight: 55930.545 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	36100	N/A	N/A	23241029
Ki (nM)	1800000	N/A	N/A	15496291

Details1. Solute carrier family 22 member 2

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Quaternary ammonium group transmembrane transporter activity
Specific Function: Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name: SLC22A2
Uniprot ID: O15244
Uniprot Name: Solute carrier family 22 member 2
Molecular Weight: 62579.99 Da

References

Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K: Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30. [PubMed:15496291]

Property	Measurement	pH	Temperature (°C)	References
Ki (nM)	300000	N/A	N/A	15496291

Details2. Solute carrier family 22 member 8

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate
Inhibitor

General Function: Sodium-independent organic anion transmembrane transporter activity
Specific Function: Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name: SLC22A8
Uniprot ID: Q8TCC7
Uniprot Name: Solute carrier family 22 member 8
Molecular Weight: 59855.585 Da

References

Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K: Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30. [PubMed:15496291]
Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T: Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83. [PubMed:15100168]
Tahara H, Kusuhara H, Chida M, Fuse E, Sugiyama Y: Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther. 2006 Mar;316(3):1187-94. Epub 2005 Nov 16. [PubMed:16291876]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 04:32

Famotidine

Identification

Structure for DB00927 (Famotidine)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

References

Enzymes

References

Transporters

References

References